Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma Clinical Trial

— RECORD-4  

Official title:

An Open-label, Multicenter Phase II Study to Examine the Efficacy and Safety of Everolimus as Second-line Therapy in the Treatment of Patients With Metastatic Renal Cell Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01491672
• Other study ID #: CRAD001L2404
• Secondary ID: 2010-020447-13
• Status: Completed
• Phase: Phase 2
• First received: December 12, 2011
• Last updated: June 2, 2016
• Start date: November 2011
• Est. completion date: May 2015

Study information

• Verified date: June 2016
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationArgentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia MedicaBrazil: Associação Fundo de Incentivo à PesquisaBulgaria: Ministry of HealthChina: Food and Drug AdministrationRussia: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

This study will evaluate everolimus as second-line therapy in patients with metastatic renal cell carcinoma. Each patient will be enrolled and stratified in one of three cohorts based upon their first-line therapy: 1) prior cytokines, 2) prior sunitinib, or 3) prior anti-VEGF therapy other than sunitinib.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 134
• Est. completion date: May 2015
• Est. primary completion date: May 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years old.

2. Patients with advanced renal cell carcinoma of a histological or cytological confirmation of clear cell (or with a component of clear cell) renal carcinoma that have previously progressed on or were intolerant to first-line therapy with sunitinib, sorafenib, pazopanib, axitinib, bevacizumab, or cytokine therapy.

3. Patients must have had prior nephrectomy (partial or total).

4. Patients with at least one measurable lesion at baseline as per the RECIST 1.0 criteria. If skin lesions are reported as target lesions, they should be documented (at baseline and at every physical exam) using color photography and a measuring device (such as a caliper) in clear focus to allow the size of the lesion(s) to be determined from the photograph.

5. Patients with a Karnofsky Performance Status = 70%.

6. Adequate bone marrow function as shown by:

1. ANC = 1.5 x 109/L,

2. Platelets = 100 x 109/L,

3. Hemoglobin >9 g/dL

7. Adequate liver function as shown by:

1. Serum bilirubin = 1.5 x ULN,

2. ALT and AST = 2.5 x ULN. Patients with known liver metastases may enroll if their AST and ALT = 5 x ULN,

3. INR < 1.3 (INR < 3 in patients treated with anticoagulants)

8. Adequate renal function: serum creatinine = 2.0 x ULN.

9. Fasting serum cholesterol =300 mg/dl OR =7.75 mmol/L AND fasting triglycerides =2.5 x ULN.

10. Written informed consent obtained before any trial related activity and according to local guidelines.

Exclusion Criteria:

1. Patients with brain metastases.

2. Patients within 4 weeks post-major surgery (e.g., intra-thoracic, intra-abdominal or intrapelvic), open biopsy, or significant traumatic injury to avoid wound healing complications.

Minor procedures and percutaneous biopsies or placement of vascular access device require 7 days prior to study entry.

3. Patients in anticipation of the need for major surgical procedure during the course of the study.

4. Patients who had radiation therapy within 4 weeks prior to start of study treatment (palliative radiotherapy to bone lesions allowed up to 2 weeks prior to study treatment start).

5. Patients with a serious non-healing wound, ulcer, or bone fracture.

6. Patients with a history of seizure(s) not controlled with standard medical therapy.

7. Patients who have received more than one prior treatment regimen for metastatic renalcell carcinoma

8. Patients who have received adjuvant therapy for RCC

9. Patients who have previously received systemic mTOR inhibitors (eg, sirolimus, temsirolimus, everolimus)

10. Patients with a known hypersensitivity to everolimus or other rapamycins (eg, sirolimus, temsirolimus) or to its excipients.

11. History or clinical evidence of central nervous system (CNS) metastases.

12. Clinically significant gastrointestinal abnormalities including, but not limited to:

1. Malabsorption syndrome:

2. Major resection of the stomach or small bowel that could affect the absorption of study drug

3. Active peptic ulcer disease

4. Inflammatory bowel disease:

i. Ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation ii. History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days prior to beginning study treatment.

13. Patients with a known history of HIV seropositivity. Screening for HIV infection at baseline is not required.

14. Active bleeding diathesis

15. Uncontrolled diabetes mellitus as defined by fasting serum glucose > 2.0 x ULN.

16. Patients who have any severe and/or uncontrolled medical conditions such as:

1. unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction

= 6 months prior to enrollment, serious uncontrolled cardiac arrhythmia,

2. active or uncontrolled severe infection,

3. history of invasive fungal infections,

4. severe hepatic impairment (Child-Pugh class C),

5. severely impaired lung function

17. History of cerebrovascular accident (CVA) including transient ischemic attack (TIA) = 6 months before start of study treatment.

18. History of pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible.

19. Patients who have a history of another primary malignancy and off treatment for = 3 years, with the exception of non-melanoma skin cancer and carcinoma in situ of the uterine cervix or breast, and localized cancer of the bladder (T1) and prostate (T1 - T2).

20. Female patients who are pregnant or nursing (lactating).

21. Adults of reproductive potential who are not using effective birth control methods.

Adequate contraceptives must be used throughout the trial and for 8 weeks after last study drug administration in female patients. Women of child-bearing potential must have a negative serum pregnancy test within 7 days prior to first administration of study drug.

22. Patients who are using other investigational agents or who had received investigational drugs = 2 weeks prior to study treatment start. This should not include sunitinib, sorafenib, axitinib, pazopanib and cytokines.

23. Patients unwilling or unable to comply with the protocol.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Renal Cell
• Metastatic Renal Cell Carcinoma

Intervention

Drug:
• RAD001
Study drug was supplied as 5 mg tablets in blister packs.

Locations

Country	Name	City	State
Argentina	Novartis Investigative Site	Rio Negro	Viedma
Argentina	Novartis Investigative Site	Tucuman
Brazil	Novartis Investigative Site	Barretos	SP
Brazil	Novartis Investigative Site	Florianopolis	SC
Brazil	Novartis Investigative Site	São Paulo	SP
Brazil	Novartis Investigative Site	São Paulo	SP
Bulgaria	Novartis Investigative Site	Sofia
China	Novartis Investigative Site	Beijing	Beijing
China	Novartis Investigative Site	Beijing
China	Novartis Investigative Site	Guangzhou
China	Novartis Investigative Site	Hangzhou	Zhejiang
China	Novartis Investigative Site	Shanghai
Russian Federation	Novartis Investigative Site	Leningrad Region	Russia
Russian Federation	Novartis Investigative Site	Moscow	Russia
Russian Federation	Novartis Investigative Site	Nizhny Novgorod	Russia
Russian Federation	Novartis Investigative Site	Obninsk	Russia
United States	Memorial Sloan Kettering Cancer Center	NY	New York

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Argentina,  Brazil,  Bulgaria,  China,  Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free Survival (PFS) - All Participants	PFS during second-line treatment was defined as the time from the date of enrollment to the date of the first documented disease progression or death due to any cause. The primary analysis of PFS was based on a local radiology review of CT scans and MRI collected until the participant experienced disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0.	20 months	No
Secondary	Duration of PFS for Each First-line Treatment Cohort	Duration of PFS during second-line treatment was defined as the time from the date of enrollment to the date of the first documented disease progression or death due to any cause. Participants' assessment was based on the local radiological data according to the RECIST 1.0 Criteria.	20 months	No
Secondary	Overall Survival (OS)	OS was defined as the time from date of enrollment to date of death due to any cause.	28 months	No
Secondary	Clinical Benefit Rate (CBR)	CBR was defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) or stable disease based on the local radiological data according to the RECIST 1.0 criteria.	20 months	No
Secondary	Objective Response Rate (ORR)	ORR was defined as the proportion of participants with best overall response of CR or PR based on the local radiological data according to the RECIST 1.0 Criteria	20 months	No
Secondary	Duration of Response (DoR)	DoR was defined as the time from the first occurrence of PR or CR (as per local radiological review) until the date of the first documented disease progression or death due to underlying cancer.	20 months	No